Paul A. Friedman, Director at MADRIGAL PHARMACEUTICALS, INC. (MDGL), sold 52,540 shares at $248.59 ($12.9M) on 2024-04-08, disclosed to the SEC on 2024-04-10.
Scheduled sale ($12.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $242.95 | 1,441 | $350K | 2.7% |
| 2 | $242.95 | 1,441 | $350K | 2.7% |
| 3 | $244.12 | 3,730 | $911K | 7.0% |
| 4 | $244.12 | 3,730 | $911K | 7.0% |
| 5 | $244.86 | 5,663 | $1.4M | 10.7% |
| 6 | $244.86 | 5,663 |
| $1.4M |
| 10.7% |
| 7 | $245.71 | 2,078 | $511K | 3.9% |
| 8 | $245.71 | 2,078 | $511K | 3.9% |
| 9 | $246.96 | 5,028 | $1.2M | 9.6% |
| 10 | $246.96 | 5,028 | $1.2M | 9.6% |
| 11 | $247.76 | 3,464 | $858K | 6.6% |
| 12 | $247.76 | 3,464 | $858K | 6.6% |
| 13 | $248.59 | 4,866 | $1.2M | 9.4% |
| 14 | $248.59 | 4,866 | $1.2M | 9.4% |
| Total | $246.19 avg | 52,540 | $12.9M | 100% |
| Filing → |
| MDGL | SELL | 2025-12-12 | $26.5M | — | Filing → |
| MDGL | SELL | 2025-08-13 | $95.1M | — | Filing → |
| MDGL | SELL | 2025-08-13 | $30.6M | — | Filing → |